Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective. Adjuvant systemic chemotherapy increases survival of primary malignant glioma patients beyond 12–18 months. The only interstitial chemotherapy treatment approved for malignant glioma is Gliadel® wafer containing carmustine (BCNU) placed in the resection cavity at surgery. Analysis of a large trial by Westphal and colleagues (n = 240) showed a 29% risk reduction (P = 0.03) in the BCNU wafer-treated group over the course of the 30-month trial. Long-term follow-up of these patients was undertaken to determine the survival benefit at 2 and 3 years.
Methods. Survival proportions for the placebo and treatment groups over the 56-month study were estimated by the Kaplan-Meier method. Multiple-regression analyses using the Cox proportional hazards model included prognostic factors of age, KPS, and tumor type. A secondary analysis was conducted for 207 GBM patients.
Results. Of the 59 patients available for long-term follow-up, 11 were alive at 56 months: 9 had received BCNU wafers and 2 had received placebo wafers. Median survival of patients treated with BCNU wafers was 13.8 months vs 11.6 months in placebo-treated patients (P = 0.017) with a hazard ratio of 0.73 (P = 0.018), representing a 27% significant risk reduction. This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years. Two of 207 GBM patients remained alive at the end of the follow-up period, both in the BCNU wafer-treated group.
Conclusion. Malignant glioma patients treated with BCNU wafers at the time of initial surgery in combination with radiation therapy demonstrated a survival advantage at 2 and 3 years follow-up compared with placebo.
- Brem, H, Piantadosi, S, Burger, PC, Walker, M, Selker, R, Vick, NA, Black, K, Sisti, M, Brem, S, Mohr, G (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.. Lancet 345: pp. 1008-1012 CrossRef
- CBTRUS (2004) Statistical Report: Primary Brain Tumors in the United States, 1997–2001. Published by the Central Brain Tumor Registry of the United States
- Ekman, M, Westphal, M (2005) Cost of brain tumour in Europe.. Eur J Neurol 12: pp. 45-49
- Fine, HA, Dear, KB, Loeffler, JS, Black, PM, Canellos, GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.. Cancer 71: pp. 2585-2597
- Gutin, PH, Prados, MD, Phillips, TL, Wara, WM, Larson, DA, Leibel, SA, Sneed, PK, Levin, VA, Weaver, KA, Silver, P (1991) External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2.. Int J Radiat Oncol Biol Phys 21: pp. 601-606
- Leibel, SA, Gutin, PH, Wara, WM, Silver, PS, Larson, DA, Edwards, MS, Lamb, SA, Ham, B, Weaver, KA, Barnett, C (1989) Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas.. Int J Radiat Oncol Biol Phys 17: pp. 1129-1139
- Meldorf MG, Riddle VD, Gliadel Multicenter Trial Group, Agarwal S (2003) Long-term efficacy of local chemotherapy with biodegradable carmustine implants (Gliadel) in high-grade malignant gliomas. Paper presented at: American Association of Neurological Surgeons (AASN) 2003 Annual Meeting Scientific Program; April 26, 2003; San Diego, CA
- Stewart, LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.. Lancet 359: pp. 1011-1018
- Valtonen, S, Timonen, U, Toivanen, P, Kalimo, H, Kivipelto, L, Heiskanen, O, Unsgaard, G, Kuurne, T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.. Neurosurgery 41: pp. 44-48 CrossRef
- Westphal, M, Hilt, DC, Bortey, E, Delavault, P, Olivares, R, Warnke, PC, Whittle, IR, Jaaskelainen, J, Ram, Z (2003) A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.. Neuro-oncol 5: pp. 79-88 CrossRef
- Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
Volume 148, Issue 3 , pp 269-275
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Keywords: BCNU; brain neoplasms; carmustine; chemotherapy; glioblastoma multiforme; Kaplan-Meier; malignant glioma; neurosurgery; survival analysis.
- Industry Sectors
- Author Affiliations
- A1. Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
- A2. Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Turkey
- A3. Pharm Athene, Inc., Maryland, USA
- A4. Ascend Therapeutics, VA, USA
- A5. Athero Genics, Inc., Georgia, USA